FEDERAL · 42 U.S.C. · Chapter 6A
Clinical evaluation units at National Institutes of Health
42 U.S.C. § 300cc–11
Title42 — The Public Health and Welfare
Chapter6A — PUBLIC HEALTH SERVICE
SubchapterXXI
PartB
Current throughPub. L. 119-99
This text of 42 U.S.C. § 300cc–11 (Clinical evaluation units at National Institutes of Health) is published on Counsel Stack Legal Research, covering United States primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.
Bluebook
42 U.S.C. § 300cc–11.
Text
(a)In general
The Secretary, acting through the Director of the National Cancer Institute and the Director of the National Institute of Allergy and Infectious Diseases, shall for each such Institute establish a clinical evaluation unit at the Clinical Center at the National Institutes of Health. Each of the clinical evaluation units—
(1)shall conduct clinical evaluations of experimental treatments for acquired immune deficiency syndrome developed within the preclinical drug development program, including evaluations of methods of diagnosing immune deficiency and evaluations of methods of predicting, diagnosing, preventing, and treating opportunistic cancers and infectious diseases; and
(2)may conduct clinical evaluations of experimental treatments for such syndrome that are developed by
Free access — add to your briefcase to read the full text and ask questions with AI
Source Credit
History
(July 1, 1944, ch. 373, title XXIII, §2311, as added Pub. L. 100–607, title II, §201(4), Nov. 4, 1988, 102 Stat. 3066; amended Pub. L. 103–43, title XVIII, §1811(2), June 10, 1993,107 Stat. 199.)
Editorial Notes
Editorial Notes
Prior Provisions
A prior section 300cc–11, act July 1, 1944, §2312, was successively renumbered by subsequent acts and transferred, see section 238i of this title.
Amendments
1993—Subsec. (a)(1). Pub. L. 103–43 inserted before semicolon at end ", including evaluations of methods of diagnosing immune deficiency and evaluations of methods of predicting, diagnosing, preventing, and treating opportunistic cancers and infectious diseases".
Prior Provisions
A prior section 300cc–11, act July 1, 1944, §2312, was successively renumbered by subsequent acts and transferred, see section 238i of this title.
Amendments
1993—Subsec. (a)(1). Pub. L. 103–43 inserted before semicolon at end ", including evaluations of methods of diagnosing immune deficiency and evaluations of methods of predicting, diagnosing, preventing, and treating opportunistic cancers and infectious diseases".
Cite This Page — Counsel Stack
Bluebook (online)
42 U.S.C. § 300cc–11, Counsel Stack Legal Research, https://law.counselstack.com/usc/42/300cc–11.